Strategikon offers cloud-based solutions that optimize and accelerate the budgeting, planning, outsourcing, and vendor management of clinical trials. Its flagship product, Clinical Maestro, is an end-to-end outsourcing management platform that replaces manual processes and outdated procurement tools while reducing regulatory compliance risk related to vendor oversight. The system was developed by financial and clinical business operations executives with Sponsor and Clinical Service Provider experience. Strategikon serves global pharma and biotech clients across the US, Europe, and Japan. The company is based in San Francisco and is led by CEO Anca Copaescu. Strategikon recently closed an over-subscribed $7.0M Series A1 financing round and plans to use the proceeds to build out sales and customer success teams to support and scale growth. Strategikon Pharma develops Clinical Maestro, a cloud-based platform that modernizes outsourcing for clinical programs by enabling sponsors, vendors, and service providers to plan studies, model and manage clinical contracts systematically. The platform is designed to speed budgeting, sourcing and management while improving accuracy and reducing effort. The company announced the close of a Series A financing to support its growth. The new capital will be used to expand Strategikon's global footprint in Europe and Asia, develop new and enhance existing applications in the Clinical Maestro ecosystem, and expand the breadth and depth of professional services to improve customer experience and support. CEO Anca Copaescu said Clinical Maestro addresses long, unresolved pain points in clinical study outsourcing and financial management and will enable the company to attract new talent.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2024